Arenavirus monoclonal antibodies and uses

US11198723B2 · kind B2 · utility

Inventors

• Luis M. Branco · Germantown, US
• Robert F. Garry · New Orleans, US
• James E. Robinson · Genval, BE
• Erica Ollmann Saphire · Solana Beach, US
• Kathryn M. HASTIE · Village of La Jolla, US
• Thomas W. Geisbert · Albany, US

Key dates

• Filing date: Dec 5, 2017
• Grant date: Dec 14, 2021
• Expiry date: Dec 5, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/10011
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are compositions comprising arenavirus monoclonal antibodies, as well as therapeutic, diagnostic, and preventative methods using the novel antibodies. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules, peptides) that inhibit Old World arenavirus infectivity, including LASV and LCMV. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains. Diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses are also disclosed, as well as new tools and methods for the design, production, and use of arenavirus monoclonal antibodies, including expression in engineered bacterial- and mammalian-based systems.